{
    "clinical_study": {
        "@rank": "51931", 
        "acronym": "C-015-404", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1 Aeras404 (5ug H4/100nmol IC31) or Placebo", 
                "arm_group_type": "Experimental", 
                "description": "1 Dose; Subject \u2265 168 to \u2264 196 days of age"
            }, 
            {
                "arm_group_label": "Cohort 2 AERAS-404 (5ug H4/500nmol IC31) or Placebo", 
                "arm_group_type": "Experimental", 
                "description": "1 Dose; Subject \u2265 168 to \u2264 196 days of age"
            }, 
            {
                "arm_group_label": "Cohort 3A AERAS-404 (5ug H4/500nmol IC31) or Placebo", 
                "arm_group_type": "Experimental", 
                "description": "2 Doses; Subject \u2265 168 to \u2264 189 days of age"
            }, 
            {
                "arm_group_label": "Cohort 3B AERAS-404 (15ug H4/500nmol IC31) or Placebo", 
                "arm_group_type": "Experimental", 
                "description": "2 Doses; Subject \u2265 168 to \u2264 189 days of age"
            }, 
            {
                "arm_group_label": "Cohort 4 AERAS-404 (15ug H4/500nmol IC31) or Placebo", 
                "arm_group_type": "Experimental", 
                "description": "3 Doses; Subject \u2265 84 to \u2264 98 days of age"
            }, 
            {
                "arm_group_label": "Cohort 5 AERAS-404 (50ug H4/500nmol IC31) or Placebo", 
                "arm_group_type": "Experimental", 
                "description": "3 Doses; Subject \u2265 84 to \u2264 98 days of age"
            }, 
            {
                "arm_group_label": "Cohort 6 AERAS-404 (dose level pending) or Placebo", 
                "arm_group_type": "Experimental", 
                "description": "3 Doses; Subject \u2265 64 to \u2264 83 days of age"
            }
        ], 
        "brief_summary": {
            "textblock": "Phase I/II, randomized, double-blind, placebo-controlled, safety, immunogenicity and\n      dose-range finding study of AERAS-404 Tuberculosis (TB) vaccine administered intramuscularly\n      in Bacille Calmette-Guerin (BCG) primed infants."
        }, 
        "brief_title": "Phase 1/II, Safety and Immunogenicity Study of AERAS-404 in BCG-Primed Infants", 
        "completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Tuberculosis", 
        "condition_browse": {
            "mesh_term": "Tuberculosis"
        }, 
        "detailed_description": {
            "textblock": "This is a Phase I/II, randomized, double-blind, placebo-controlled, safety, immunogenicity\n      and dose-range finding study in HIV-uninfected, HIV-unexposed, BCG-primed infants.  The\n      study vaccine AERAS-404 or placebo will be administered without concomitant EPI vaccines\n      (Cohorts 1 to 5, N = 159 subjects) and with concomitant EPI vaccines (Cohort 6, N = 70\n      subjects).  Study vaccine or placebo will be administered as a single dose (injection) at\n      Study Day 0 ( \u2265168 to \u2264 196 days of age, Cohorts 1 and 2), a 2-dose schedule at Study Day 0\n      (\u2265 168 to \u2264 189 days of age) and Study Day 28 (Cohorts 3A and 3B) or a 3-dose schedule at\n      Study Day 0 (\u2265 84 to \u2264 98 days of age), Study Day 42 and Study Day 98 (Cohorts 4 and 5).\n      Subjects in Cohort 6 will receive the study vaccine or placebo at Study Day 0 (\u2265 64 to \u2264 83\n      days of age), Study Day 28 (\u2265 91 to \u2264 105 days of age), and Study Day 210 (\u2265 273 to \u2264 287\n      days of age). A cohort will enroll once safety in the previous cohort has been established."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "INCLUSION CRITERIA\n\n          1. Age at time of entry:\n\n             Cohorts 1 to 6\n\n               -  Cohorts 1 and 2: \u2265 168 to \u2264 196 days\n\n               -  Cohorts 3A and 3B: \u2265 168 to \u2264 189 days\n\n               -  Cohorts 4 and 5: \u2265 84 to \u2264 98 days (\u2265 2 weeks after receipt of EPI vaccine doses\n                  at 10 weeks of age)\n\n               -  Cohort 6 - coincident with EPI vaccine doses at 10 weeks of age (\u2265 64 to \u2264 83\n                  days of age)\n\n          2. Source documentation of birth weight \u2265 2.5 kg.\n\n          3. Documented BCG vaccination within 72 hours of birth.\n\n          4. Documented receipt of all age-appropriate EPI vaccines, except Rotavirus, for Cohorts\n             4 to 6 (see Appendix II).\n\n          5. Source documentation of a negative HIV status in the mother, from any time during\n             pregnancy with this child through randomization.\n\n          6. Documentation of infant HIV negative exposure or infection status with negative HIV\n             ELISA and HIV DNA PCR tests.\n\n          7. Parent or legal guardian able and willing to provide signed informed consent.\n\n          8. Participant/parent/legal guardian able to attend all scheduled visits and to comply\n             with all trial procedures.\n\n        EXCLUSION CRITERIA\n\n          1. History of TB exposure in household or non-household contact.\n\n          2. History/Evidence of TB disease or infection.\n\n          3. Quantiferon positive.\n\n          4. Prior TST test.\n\n          5. Any one of Anemia, Neutropenia, Thrombocytopenia, SGPT (ALT), SGOT (AST) or\n             Creatinine \u2265 Grade 2\n\n          6. Receipt of a live vaccine within 28 days prior to randomization.\n\n          7. Receipt or planned receipt of any investigational vaccine.\n\n          8. Known or suspected congenital immunodeficiency.\n\n          9. Receipt of immunosuppressive therapy or long-term systemic corticosteroid therapy\n             (prednisone or equivalent for more than 2 consecutive weeks within the past 3\n             months).\n\n         10. Known or suspected autoimmune disease\n\n         11. Hypersensitivity to any of the vaccine components, or history of a life-threatening\n             reaction to a vaccine containing any of the same substances as the vaccine used in\n             the trial.\n\n         12. Participation in another clinical trial for an investigational product (IP).\n\n         13. Bleeding disorder or receipt of anticoagulants in the 3 weeks preceding\n             randomization, contraindicating IM vaccination.\n\n         14. Chronic illness that, in the opinion of the investigator, is at a stage where it\n             might interfere with trial conduct or completion.\n\n         15. Febrile illness (temperature \u2265 100.4\u00b0F [\u2265 38.0\u00b0C]) within 24 hours prior to\n             randomization.\n\n             Note: A subject may enroll after recovery from febrile illness if the subject is\n             still within the age window.\n\n         16. Systemic antibiotic use within 48 hours prior to randomization."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "196 Days", 
            "minimum_age": "64 Days"
        }, 
        "enrollment": {
            "#text": "229", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01861730", 
            "org_study_id": "C-015-404/ IMPAACT P1113", 
            "secondary_id": [
                "U01AI068632", 
                "C-015-404"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cohort 1 Aeras404 (5ug H4/100nmol IC31) or Placebo", 
                    "Cohort 2 AERAS-404 (5ug H4/500nmol IC31) or Placebo", 
                    "Cohort 3A AERAS-404 (5ug H4/500nmol IC31) or Placebo", 
                    "Cohort 3B AERAS-404 (15ug H4/500nmol IC31) or Placebo", 
                    "Cohort 4 AERAS-404 (15ug H4/500nmol IC31) or Placebo", 
                    "Cohort 5 AERAS-404 (50ug H4/500nmol IC31) or Placebo", 
                    "Cohort 6 AERAS-404 (dose level pending) or Placebo"
                ], 
                "description": "AERAS-404 is an investigational vaccine manufactured by Sanofi Pasteur (SP) and Statens Serum Institute (SSI).  AERAS-404 has two components: the H4 antigen and the IC31 adjuvant. The reconstitution of the vaccine components, H4 antigen (manufactured at SP) and IC31 adjuvant (supplied by SSI), will take place at the clinical research site (CRS) prior to injection.", 
                "intervention_name": "AERAS-404", 
                "intervention_type": "Biological", 
                "other_name": "H4"
            }, 
            {
                "arm_group_label": [
                    "Cohort 1 Aeras404 (5ug H4/100nmol IC31) or Placebo", 
                    "Cohort 2 AERAS-404 (5ug H4/500nmol IC31) or Placebo", 
                    "Cohort 3A AERAS-404 (5ug H4/500nmol IC31) or Placebo", 
                    "Cohort 3B AERAS-404 (15ug H4/500nmol IC31) or Placebo", 
                    "Cohort 4 AERAS-404 (15ug H4/500nmol IC31) or Placebo", 
                    "Cohort 5 AERAS-404 (50ug H4/500nmol IC31) or Placebo", 
                    "Cohort 6 AERAS-404 (dose level pending) or Placebo"
                ], 
                "description": "Tris buffered saline (10mM Tris, pH 7.4, 150nm sodium chloride).", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological", 
                "other_name": "Tris buffered saline"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "BCG Vaccinated", 
            "HIV Negative"
        ], 
        "lastchanged_date": "March 14, 2014", 
        "location": [
            {
                "contact": {
                    "email": "violari@mweb.co.za", 
                    "last_name": "Avy Violari, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Johannesburg", 
                        "country": "South Africa", 
                        "state": "Guateng", 
                        "zip": "2091"
                    }, 
                    "name": "PHRU, Chris Hani Baragwanath Hospital"
                }, 
                "investigator": {
                    "last_name": "Avy Violari, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "lfairlie@wrhi.ac.za", 
                    "last_name": "Lee Fairlie, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Johannesburg", 
                        "country": "South Africa", 
                        "state": "Hillbrow", 
                        "zip": "2001"
                    }, 
                    "name": "Shandukani Research"
                }, 
                "investigator": {
                    "last_name": "Lee Fairlie, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mcot@sun.ac.za", 
                    "last_name": "Mark F Cotton, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Cape Town", 
                        "country": "South Africa", 
                        "state": "Tygerberg", 
                        "zip": "7505"
                    }, 
                    "name": "KID-CRU, Tygerberg Hospital"
                }, 
                "investigator": {
                    "last_name": "Mark F Cotton, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "South Africa"
        }, 
        "number_of_arms": "7", 
        "official_title": "Phase 1/II, Safety and Immunogenicity Study of a Recombinant Protein Tuberculosis Vaccine (AERAS-404) in BCG-Primed Infants", 
        "other_outcome": [
            {
                "description": "T-cell response, as measured by Intracellular Cytokine Staining (ICS) following stimulation with peptide pools spanning the vaccine antigens, will be used to assess immunogenicity.", 
                "measure": "Assess the immunogenicity of a 3-dose AERAS-404 regimen in HIV-uninfected, HIV-unexposed, BCG-primed infants.", 
                "safety_issue": "No", 
                "time_frame": "Subjects will be followed for up to 1 year and 4 months."
            }, 
            {
                "description": "Safety and immunogenicity analyses will be reviewed for the selection of the appropriate dose regimen", 
                "measure": "Select an appropriate dose regimen for AERAS-404 in HIV-uninfected, HIV-unexposed, BCG-primed infants.", 
                "safety_issue": "Yes", 
                "time_frame": "After all subjects in Cohorts 4 and 5 have completed Study Day 126, the safety and immunogenicity data from these Cohorts will be evaluated.  The data will inform the decision on the study vaccine dose for Cohort 6."
            }, 
            {
                "description": "Antibody concentration levels at 12 months of age for all Cohorts, and in addition at 28 days post second study vaccine dose (Study Day 56) for Cohort 6 will be presented.  Summaries will include antibody titers to Tetanus toxoid vaccine (tetanus; given at 6, 10, 14 weeks of age), and Haemophilus influenza B conjugate vaccine (given at 6, 10, 14 weeks of age).  Responses to other EPI vaccines may also be assessed.", 
                "measure": "Explore interactions between AERAS-404 and EPI vaccines.", 
                "safety_issue": "Yes", 
                "time_frame": "Antibody concentration blood samples taken when subjects reach 12 months of age for all Cohorts and in addition, 28 post second study vaccine dose (Study Day 56) for subjects in Cohort 6 only."
            }, 
            {
                "measure": "Assess the immunogenicity of a 2-dose AERAS-404 regimen in HIV-uninfected, HIV-unexposed, BCG-primed infants.", 
                "safety_issue": "No", 
                "time_frame": "Subjects will have Immunology samples taken at multiple time points for up to 1 year and 4 months."
            }
        ], 
        "overall_contact": {
            "email": "Zshi@aeras.org", 
            "last_name": "Zhongkai Shi, MD"
        }, 
        "overall_contact_backup": {
            "email": "GRobertson@aeras.org", 
            "last_name": "Gavin Robertson"
        }, 
        "overall_official": [
            {
                "affiliation": "Aeras", 
                "last_name": "Zhongkai Shi, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Perinatal HIV Research Unit", 
                "last_name": "Avy Violari, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "South Africa: Medicines Control Council", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Adverse Events and Serious Adverse Events (SAE) will be collected on subjects throughout their participation in the study. Solicited adverse events are captured 28 days post each vaccination.  Evaluation of the safety profile of AERAS-404 will be performed using data from all subjects who received at least one dose and has 7 days of safety data, and will be summarized by cohort and treatment group.  The number (percentage) of subjects with any adverse event (including solicited, unsolicited, and serious adverse events) will be summarized by Medical Dictionary for Regulatory Activities (MedDRA) system organ class and Preferred Term.  Additional summaries will present the number (percentage) of subjects with any adverse events by severity and by relationship to study vaccine; parameters evaluable by the Aeras 404 Pediatric Toxicity Table provided in the protocol, will be summarized by severity corresponding to Toxicity Grade, as appropriate.", 
            "measure": "Investigate the safety of AERAS-404 in HIV-uninfected, HIV-unexposed, BCG-primed infants.", 
            "safety_issue": "Yes", 
            "time_frame": "Subjects will be followed for up to 1 year and 4 months."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01861730"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The number and percentage of subjects who are enrolled into the three-dose regimen (Cohorts 4-6) with solicited and unsolicited AEs (including serious adverse events [SAEs], local and systemic reactions, and clinical laboratory values or vital sign values recorded as newly abnormal following study vaccination) recorded post-vaccination will be summarized to address the secondary safety objective of the study.  Subjects in Cohorts 4 and 5 will be followed for : 1 year and 3 months, Cohort 6: 1 year 4 months and Solicited adverse events are captured 28 days post each vaccination.", 
            "measure": "Investigate the safety of a 3-dose AERAS-404 regimen in HIV-uninfected, HIV-unexposed, BCG-primed infants", 
            "safety_issue": "Yes", 
            "time_frame": "Subjects will be followed for up to 1 year and 4 months."
        }, 
        "source": "Aeras", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Statens Serum Institut", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Sanofi Pasteur, a Sanofi Company", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "International Maternal Pediatric Adolescent AIDS Clinical Trials Group", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Aeras", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}